Publications

Publications

Here we highlight some of our recent publications.

Uro-oncology

• Estimation of the incidence of urachal cancer: A systematic review and meta-analysis of registry-based studies. Olah C, Kubik A, Mátrai P, Engh MA, Barna V, Hegyi P, Reis H, Nyirády P, Szarvas T. Urol Oncol. 2024 Apr 15:S1078-1439(24)00381-8. doi: 10.1016/j.urolonc.2024.03.011. Online ahead of print.
• Magnetic Resonance Imaging in Prostate Cancer Screening: A Systematic Review and Meta-Analysis. Fazekas T, Shim SR, Basile G, Baboudjian M, Kói T, Przydacz M, Abufaraj M, Ploussard G, Kasivisvanathan V, Rivas JG, Gandaglia G, Szarvas T, Schoots IG, van den Bergh RCN, Leapman MS, Nyirády P, Shariat SF, Rajwa P.JAMA Oncol. 2024 Apr 5:e240734. doi: 10.1001/jamaoncol.2024.0734. Online ahead of print.
• Efficacy of immune checkpoint inhibitor therapy for advanced urothelial carcinoma in real-life clinical practice: results of a multicentric, retrospective study. Váradi M, Horváth O, Módos O, Fazekas T, Grunewald CM, Niegisch G, Krafft U, Grünwald V, Hadaschik B, Olah C, Maráz A, Furka A, Szűcs M, Nyirády P, Szarvas T. Sci Rep. 2023 Oct 13;13(1):17378. doi: 10.1038/s41598-023-44103-9.
• Poly (ADP-ribose) Polymerase Inhibitors Have Comparable Efficacy with Platinum Chemotherapy in Patients with BRCA-positive Metastatic Castration-resistant Prostate Cancer. A Systematic Review and Meta-analysis. Fazekas T, Széles ÁD, Teutsch B, Csizmarik A, Vékony B, Kói T, Ács N, Hegyi P, Hadaschik B, Nyirády P, Szarvas T. Eur Urol Oncol. 2023 Sep 16:S2588-9311(23)00174-8. doi: 10.1016/j.euo.2023.09.001. Online ahead of print.
• Comparative proteome and serum analysis identified FSCN1 as a marker of abiraterone resistance in castration-resistant prostate cancer. Csizmarik A, Nagy N, Keresztes D, Váradi M, Bracht T, Sitek B, Witzke K, Puhr M, Tornyi I, Lázár J, Takács L, Kramer G, Sevcenco S, Maj-Hes A, Hadaschik B, Nyirády P, Szarvas T. Prostate Cancer Prostatic Dis. 2023 Aug 26. doi: 10.1038/s41391-023-00713-y
• SOX2 dosage sustains tumor-promoting inflammation to drive disease aggressiveness by modulating the FOSL2/IL6 axis. Njouendou AJ, Szarvas T, Tiofack AAZ, Kenfack RN, Tonouo PD, Ananga SN, Bell EHMD, Simo G, Hoheisel JD, Siveke JT, Lueong SS. Mol Cancer. 2023 Mar 17;22(1):52. doi: 10.1186/s12943-023-01734-w.
• Clinical sequencing identifies potential actionable alterations in a high rate of urachal and primary bladder adenocarcinomas. Varadi M, Nagy N, Reis H, Hadaschik B, Niedworok C, Modos O, Szendroi A, Ablat J, Black PC, Keresztes D, Csizmarik A, Olah C, Gaisa NT, Kiss A, Timar J, Toth E, Csernak E, Gerstner A, Mittal V, Karkampouna S, Kruithof de Julio M, Gyorffy B, Bedics G, Rink M, Fisch M, Nyirady P, Szarvas T. Cancer Med. 2023 Apr;12(7):9041-9054. doi: 10.1002/cam4.5639.
• Therapeutic sensitivity to standard treatments in BRCA positive metastatic castration-resistant prostate cancer patients-a systematic review and meta-analysis. Fazekas T, Széles ÁD, Teutsch B, Csizmarik A, Vékony B, Váradi A, Kói T, Lang Z, Ács N, Kopa Z, Hegyi P, Hadaschik B, Grünwald V, Nyirády P, Szarvas T. Prostate Cancer Prostatic Dis. 2023 Dec;26(4):665-672. doi: 10.1038/s41391-022-00626-2.

PDAC and its TME

• Grünwald BT, Devisme A, Andrieux G, Vyas F, Aliar K, McCloskey CW, Macklin A, Jang GH, Denroche R, Romero JM, Bavi P, Bronsert P, Notta F, O’Kane G, Wilson J, Knox J, Tamblyn L, Udaskin M, Radulovich N, Fischer SE, Boerries M, Gallinger S, Kislinger T, Khokha R. Spatially confined sub-tumor microenvironments in pancreatic cancer. Cell. 2021 Oct 28;184(22):5577-5592.e18. doi: 10.1016/j.cell.2021.09.022. Epub 2021 Oct 12. PMID: 34644529. https://pubmed.ncbi.nlm.nih.gov/34644529/
• Cadavid JL, Latour S, Nowlan F, Co IL, Landon-Brace N, Wouters BG, Grünwald BT, Nitz M, Jackson HW, McGuigan AP. An Engineered Paper-Based 3D Coculture Model of Pancreatic Cancer to Study the Impact of Tissue Architecture and Microenvironmental Gradients on Cell Phenotype. Adv Healthc Mater. 2023 Jun;12(14):e2201846. doi: 10.1002/adhm.202201846. Epub 2022 Nov 7. PMID: 36308030.
  https://pubmed.ncbi.nlm.nih.gov/36308030/

Sex-disparities in Cancer

• Aliar K, Waterhouse HR, Vyas F, Krebs N, Zhang B, Poulton E, Chan N, Gonzalez R, Jang GH, Bronsert P, Fischer SE, Gallinger S, Grünwald BT, Khokha R. Hourglass, a rapid analysis framework for heterogeneous bioimaging data, identifies sex disparity in IL-6/STAT3-associated immune phenotypes in pancreatic cancer. J Pathol. 2023 Dec;261(4):413-426. doi: 10.1002/path.6199. Epub 2023 Sep 28. PMID: 37768107.
  https://pubmed.ncbi.nlm.nih.gov/37768107/
• Hermann CD, Schoeps B, Eckfeld C, Munkhbaatar E, Kniep L, Prokopchuk O, Wirges N, Steiger K, Häußler D, Knolle P, Poulton E, Khokha R, Grünwald BT, Demir IE, Krüger A. TIMP1 expression underlies sex disparity in liver metastasis and survival in pancreatic cancer. J Exp Med. 2021 Nov 1;218(11):e20210911. doi: 10.1084/jem.20210911. Epub 2021 Sep 17. PMID: 34533565; PMCID: PMC8480668.
  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8480668/

Navigating heterogeneity through tools & biomarkers

• O’Kane GM, Grünwald BT, Jang GH, Masoomian M, Picardo S, Grant RC, Denroche RE, Zhang A, Wang Y, Lam B, Krzyzanowski PM, Lungu IM, Bartlett JMS, Peralta M, Vyas F, Khokha R, Biagi J, Chadwick D, Ramotar S, Hutchinson S, Dodd A, Wilson JM, Notta F, Zogopoulos G, Gallinger S, Knox JJ, Fischer SE. GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic Cancer. Clin Cancer Res. 2020 Sep 15;26(18):4901-4910. doi: 10.1158/1078-0432.CCR-19-3724. Epub 2020 Mar 10. Erratum in: Clin Cancer Res. 2022 Jun 13;28(12):2715. PMID: 32156747.
  https://pubmed.ncbi.nlm.nih.gov/32156747/
• Romero JM, Grünwald B, Jang GH, Bavi PP, Jhaveri A, Masoomian M, Fischer SE, Zhang A, Denroche RE, Lungu IM, De Luca A, Bartlett JMS, Xu J, Li N, Dhaliwal S, Liang SB, Chadwick D, Vyas F, Bronsert P, Khokha R, McGaha TL, Notta F, Ohashi PS, Done SJ, O’Kane GM, Wilson JM, Knox JJ, Connor A, Wang Y, Zogopoulos G, Gallinger S. A Four-Chemokine Signature Is Associated with a T-cell-Inflamed Phenotype in Primary and Metastatic Pancreatic Cancer. Clin Cancer Res. 2020 Apr 15;26(8):1997-2010. doi: 10.1158/1078-0432.CCR-19-2803. Epub 2020 Jan 21. PMID: 31964786.
  https://pubmed.ncbi.nlm.nih.gov/31964786/